{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:41:30Z","timestamp":1780962090779,"version":"3.54.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","elsevier.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.acuroe.2024.04.001","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T15:48:32Z","timestamp":1712072912000},"page":"345-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Is trimodal therapy the current standard for muscle-invasive bladder cancer?"],"prefix":"10.1016","volume":"48","author":[{"given":"M.","family":"L\u00f3pez Valc\u00e1rcel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Barrado Los Arcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ferri Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Cienfuegos Belmonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Duque Santana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Gajate Borau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fern\u00e1ndez Ibiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"\u00c1lvarez Maestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"L\u00f3pez Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuroe.2024.04.001_bib0005","unstructured":"Muscle-Invasive, Metastatic Bladder Cancer EAU Guidelines, 2023, On."},{"key":"10.1016\/j.acuroe.2024.04.001_bib0010","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MOU.0000000000000601","article-title":"Trimodality therapy for bladder cancer: modern management and future directions","volume":"29","author":"Pham","year":"2019","journal-title":"Curr Opin Urol"},{"issue":"6","key":"10.1016\/j.acuroe.2024.04.001_bib0020","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0025","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/COC.0000000000000471","article-title":"Comparison of outcomes in patients with muscle-invasive bladder cancer treated with radical cystectomy versus bladder preservation","volume":"42","author":"Zhong","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0030","doi-asserted-by":"crossref","first-page":"539","DOI":"10.3390\/biomedicines11020539","article-title":"The current progress and future options of multiple therapy and potential biomarkers for muscle-invasive bladder cancer","volume":"11","author":"Shi","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0035","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.semradonc.2022.10.007","article-title":"Myths about bladder preservation in muscle-invasive bladder cancer","volume":"33","author":"Elumalai","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0045","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.21037\/tau.2020.02.10","article-title":"Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer","volume":"9","author":"Tholomier","year":"2021","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0050","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0055","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","volume":"14","author":"Mitin","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0060","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1016\/j.ijrobp.2021.07.302","article-title":"NRG oncology\/RTOG 0926: phase II protocol for patients with stage T1 bladder cancer to evaluate selective bladder preserving treatment by radiation therapy concurrent with radiosensitizing chemotherapy following a thorough transurethral surgical re-staging","volume":"111","author":"Dahl","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0065","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0070","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.ijrobp.2016.12.018","article-title":"A phase 1\/2 trial of a combination of paclitaxel and trastuzumab with daily irradiation or paclitaxel alone with daily irradiation after transurethral surgery for noncystectomy candidates with muscle-invasive bladder cancer (trial NRG oncology RTOG 0524)","volume":"97","author":"Michaelson","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0075","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1200\/JCO.2010.31.5721","article-title":"Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer","volume":"29","author":"Choudhury","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0080","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.18.00537","article-title":"Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712-a randomized phase II trial","volume":"37","author":"Coen","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0085","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.ijrobp.2021.03.001","article-title":"Long-term outcomes of radical radiation therapy with hypoxia modification with biomarker discovery for stratification: 10-year update of the BCON (Bladder Carbogen Nicotinamide) phase 3 randomized trial (ISRCTN45938399)","volume":"110","author":"Song","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0090","first-page":"46","article-title":"Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer","volume":"25","author":"Hunt","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0095","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s13566-019-00411-0","article-title":"Intensity-modulated radiotherapy is superior to three-dimensional conformal radiotherapy in the trimodality management of muscle-invasive bladder cancer with daily cone beam computed tomography optimization","volume":"8","author":"Sherry","year":"2019","journal-title":"J Radiat Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0100","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clon.2019.06.005","article-title":"Adaptive radiotherapy for carcinoma of the urinary bladder: long-term outcomes with dose escalation","volume":"31","author":"Murthy","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.radonc.2021.06.011","article-title":"Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder","volume":"161","author":"Khalifa","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0110","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.clon.2023.05.002","article-title":"Acute toxicity of hypofractionated and conventionally fractionated (chemo)radiotherapy regimens for bladder cancer: an exploratory analysis from the RAIDER trial","volume":"35","author":"Huddart","year":"2023","journal-title":"Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s00345-018-2606-y","article-title":"SIU\u2013ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer","volume":"37","author":"Leow","year":"2019","journal-title":"World J Urol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0120","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.critrevonc.2015.04.006","article-title":"Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer: a systematic review of clinical trials","volume":"95","author":"Arcangeli","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0125","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1200\/JCO.2010.28.4950","article-title":"Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma","volume":"28","author":"Hoskin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.acuroe.2024.04.001_bib0130","doi-asserted-by":"crossref","first-page":"325.e15","DOI":"10.1016\/j.urolonc.2022.12.011","article-title":"Bladder only versus bladder plus pelvic lymph node chemoradiation for muscle-invasive bladder cancer","volume":"41","author":"Patel","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0135","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0140","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ijrobp.2020.11.068","article-title":"Clinical outcomes of a randomized trial of adaptive plan-of-the-day treatment in patients receiving ultra-hypofractionated weekly radiation therapy for bladder cancer","volume":"110","author":"Huddart","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0145","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.radonc.2004.11.003","article-title":"A randomised trial of accelerated radiotherapy for localised invasive bladder cancer","volume":"75","author":"Horwich","year":"2005","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0150","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259526","article-title":"Neoadjuvant chemotherapy with dose dense MVAC is associated with improved survival after radical cystectomy compared to other cytotoxic regimens: a tertiary center experience","volume":"16","author":"Lemi\u0144ski","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0155","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.juro.2008.03.024","article-title":"Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later","volume":"180","author":"Ghoneim","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0160","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.acuro.2020.10.007","article-title":"Usefulness of neoadjuvant chemotherapy in non-metastatic muscle-invasive bladder cancer","volume":"45","author":"Esper Rueda","year":"2021","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0165","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0170","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1634\/theoncologist.2015-0440","article-title":"Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis","volume":"21","author":"Yin","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0175","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.eururo.2013.06.049","article-title":"Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: a meta-analysis","volume":"65","author":"Petrelli","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0180","author":"Flaig"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0185","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0190","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0195","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0200","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clgc.2021.03.007","article-title":"Trimodality therapy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"19","author":"Royce","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0205","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.urolonc.2017.10.002","article-title":"A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"36","author":"Fahmy","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0210","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3390\/jcm12041560","article-title":"Combined modality bladder-sparing therapy for muscle-invasive bladder cancer: how (should) we do it? A narrative review","volume":"12","author":"Lemi\u0144ski","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0215","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00345-020-03440-4","article-title":"Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response","volume":"39","author":"Daro-Faye","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0220","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.urolonc.2020.10.006","article-title":"Systemic therapy in bladder preservation","volume":"41","author":"Girardi","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0225","doi-asserted-by":"crossref","first-page":"S1332","DOI":"10.1016\/j.annonc.2022.07.1817","article-title":"1739P Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502)","volume":"33","author":"Weickhardt","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2022.12.012","article-title":"Efficacy and safety of pembrolizumab (MK-3475) in combination with chemoradiotherapy versus chemoradiotherapy alone in muscle-invasive bladder cancer: the MK-3475-992\/KEYNOTE-992 trial","author":"Tissot","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"CT564","key":"10.1016\/j.acuroe.2024.04.001_bib0235","article-title":"Abstract CT564: KEYNOTE-992: a randomized phase 3 trial of pembrolizumab versus placebo in patients with muscle-invasive bladder cancer receiving concurrent chemoradiotherapy","volume":"82 (12_Supplement)","author":"Shore","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0240","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/j.ijrobp.2022.07.475","article-title":"INTACT (S\/N1806): phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer\u2014toxicity update on first 213 patients","volume":"114","author":"Singh","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0245","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006551","article-title":"Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023","volume":"11","author":"Joshi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0250","article-title":"Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial","volume":"39(15_suppl)","author":"Garcia del Muro","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0255","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1046\/j.1442-2042.2002.00443.x","article-title":"Neo\u2010adjuvant treatment of infiltrating transitional\u2010cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial","volume":"9","author":"Sousa-Escand\u00f3n","year":"2002","journal-title":"Int J Urol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0260","first-page":"697","article-title":"Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer","volume":"17","author":"Ericson","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0265","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.semradonc.2022.10.008","article-title":"Bladder preservation for muscle-invasive bladder cancer with variant histology","volume":"33","author":"Brocklehurst","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0270","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.eururo.2017.03.038","article-title":"Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder","volume":"72","author":"Seisen","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0275","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0280","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.urology.2018.07.058","article-title":"Long-term outcomes and patterns of failure following trimodality treatment with bladder preservation for invasive bladder cancer","volume":"124","author":"B\u00fcchser","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0285","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.urolonc.2021.01.013","article-title":"Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer","volume":"40","author":"Feldman","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0290","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.juro.2011.09.159","article-title":"Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer","volume":"187","author":"Eswara","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0295","article-title":"Quality of life after radical treatment for muscle invasive bladder cancer: a systematic review and meta-analysis","volume":"41(6_suppl)","author":"Francolini","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0300","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1200\/JCO.2008.19.5776","article-title":"Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0305","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19092777","article-title":"Biomarkers for predicting clinical outcomes of chemoradiation-based bladder preservation therapy for muscle-invasive bladder cancer","volume":"19","author":"Koga","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0310","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.eururo.2019.01.011","article-title":"Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer","volume":"76","author":"Efstathiou","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0315","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijrobp.2014.05.043","article-title":"Significance of ERBB2 overexpression in therapeutic resistance and cancer-specific survival in muscle-invasive bladder cancer patients treated with chemoradiation-based selective bladder-sparing approach","volume":"90","author":"Inoue","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0320","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.euros.2021.11.011","article-title":"Role of serum lymphocyte-derived biomarkers in nonmetastatic muscle-invasive bladder cancer patients treated with trimodal therapy","volume":"36","author":"Kool","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0325","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.ijrobp.2022.07.375","article-title":"Genomic determinants of response to trimodality therapy for muscle-invasive bladder cancer","volume":"114","author":"Kamran","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.acuroe.2024.04.001_bib0330","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bju.13900","article-title":"Clinical and patient-reported outcomes of SPARE \u2013 a randomised feasibility study of selective bladder preservation versus radical cystectomy","volume":"120","author":"Huddart","year":"2017","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.acuroe.2024.04.001_bib0335","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijrobp.2023.05.013","article-title":"Efficacy and safety of bladder preservation therapy in combination with atezolizumab and radiation therapy (BPT-ART) for invasive bladder cancer: interim analysis from a multicenter, open-label, prospective phase II trial","volume":"117","author":"Kimura","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624000283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578624000283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T15:47:01Z","timestamp":1717343221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578624000283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":67,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2173578624000283"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.04.001","relation":{},"ISSN":["2173-5786"],"issn-type":[{"value":"2173-5786","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Is trimodal therapy the current standard for muscle-invasive bladder cancer?","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2024.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2024.01.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}